Resources for medical professionals

The current environment presents many challenges. Mayo Clinic's highest priority is patient and staff safety. We are taking every precaution to manage patient safety to the highest standard through universal masking, enhanced safety protocols, robust screening and COVID-19 testing strategies. Mayo Clinic will continuously evaluate the circumstances at each of our sites and follow federal and state mandates.


Find resources for providers and answers to questions on referrals and testing for COVID-19 on the Medical Professionals Resource Center.

Mayo Clinic physicians are committed to collaborating with referring physicians. Telephone consultations and referrals may be arranged by contacting the Referring Physician Service. The office is available 24 hours a day, seven days a week.

To refer a patient:

Rochester, Minnesota

Contact the Referring Provider Office at 800-533-1564 (toll-free) 24 hours a day, seven days a week. Mayo Clinic hematologists are happy to discuss possible referrals with physicians and their staffs outside of Mayo Clinic.

Hematologists generally can see most patients within two weeks after the appointment request, and often can see patients within a week or less after the appointment request. Patients with urgent issues can usually be seen within 24 hours after their requests. In emergencies, patients are directly transferred to inpatient hospital care.

Resources for patients

If you think you or a loved one is eligible for CAR-T cell therapy at one of Mayo Clinic's three locations, please call the phone number below to request an appointment at the location you are interested in seeking care at. Our appointment staff will work to find the specialist who can best address your questions and needs. Please be sure to mention that you are interested in CAR-T cell therapy to ensure your request is routed correctly.

  • Minnesota: 507-284-8707
  • Arizona: 480-342-1927
  • Florida: 904-956-3309
Oct. 15, 2019
  1. Locke FL, et al. Clinical and biologic covariates of outcomes in zuma-1: A pivotal trial of axicabtagene ciloleucel (AXI-CEL; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL). Presentation. 2017 annual meeting of European Hematology Association, June 24, 2017, Madrid, Spain. Accessed Oct. 27, 2017.
  2. Neelapu SS, et al. Chimeric antigen receptor T-cell therapy: Assessment and management of toxicities. Nature Reviews Clinical Oncology. 2018;15:47.